论文部分内容阅读
〔目的〕评价Ⅲ期非小细胞肺癌（NSCLC）根治术后辅助化疗疗效及其TNM分期与预后的关系。［方法］回顾性总结68例根治术后的Ⅲ期NSCIL，其中42例于术后3～4周开始接受化疗（辅助化疗组），予以MVP或CAP方案，每4～6周重复，第一年完成4～6个疗程，第2年完成2个疗程，共6～8个疗程。另26例患者术后来行化疗（单纯手术组）。［结果］辅助化疗组和单纯手术组的5年生存率分别为42.9%和19.2%（P＜0.05），中位生存期分别为36.5个月和13.4个月。［结论］辅助化疗组疗效明显优于单纯手术组。TNM分期状况与预后密切相关，T3N0M0疗效好，胸内淋巴结受累特别是N2为Ⅲ期肺癌疗效差的主要原因。
[Objective] To evaluate the efficacy of adjuvant chemotherapy after radical resection of stage III non-small cell lung cancer (NSCLC) and the relationship between TNM staging and prognosis. [Methods] 68 cases of stage III NSCIL after radical resection were retrospectively reviewed. Among them, 42 cases received chemotherapy (adjuvant chemotherapy group) 3 to 4 weeks after operation and were given MVP or CAP regimen, repeated every 4 to 6 weeks. Years to complete 4 to 6 courses, the second year to complete 2 courses, a total of 6 to 8 courses. Another 26 patients received chemotherapy after surgery (surgical group). [Results] The 5-year survival rates of the adjuvant chemotherapy group and the surgery alone group were 42.9% and 19.2%, respectively (P<0.05). The median survival time was 36.5 months and 13.4 months, respectively. [Conclusion] The effect of adjuvant chemotherapy was obviously better than that of the simple surgery group. TNM staging status is closely related to prognosis. T3N0M0 has good curative effect. The involvement of intrathoracic lymph nodes, especially N2, is the main reason for poor efficacy of stage III lung cancer.